Systematic ReviewSystematic Review
Open Access

JAK2-V617F mutation among blood donors

A meta-analysis

Mada H. Alsharif, Eman M. Mansory, Amjad A. Alharazi and Maha A. Badawi
Saudi Medical Journal December 2024, 45 (12) 1289-1304; DOI: https://doi.org/10.15537/smj.2024.45.12.20240594

References

  1. 1.↵
    1. Perner F,
    2. Perner C,
    3. Ernst T,
    4. Heidel FH
    . Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation. Cells 2019; 8: 854.
    OpenUrl
  2. 2.↵
    1. Tefferi A,
    2. Barbui T
    . Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol 2023; 98: 1465-1487.
    OpenUrlPubMed
  3. 3.↵
    1. Al-Nuri RNA-D
    . The Frequency of Blood Donors and Polycythemia among General Population in Nineveh Governorate, Iraq. Ann Coll Med Mosul 2021; 42: 141-147.
    OpenUrl
  4. 4.↵
    Association for the Advancement of Bloof & Biotherapies. Hemoglobin Screening/Iron Management. [Accessed 2024 March]. Available from: https://www.aabb.org/regulatory-and-advocacy/regulatory-affairs/regulatory-for-blood/donor-safety-screening-and-testing/hemoglobin-screening-iron-management
  5. 5.↵
    P Joint United Kingdom (UK) Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee. Polycythaemia and Raised Haemoglobin. DSG-WB Edition 203, Release 58 [Accessed 2024 July 7th]. Available from: https://www.transfusionguidelines.org/dsg/wb/guidelines/po006-polycythaemia
  6. 6.
    Lifeblood Australian Red Cross. Haemoglobin, iron health and blood donation. [Accessed 2024 July 7th]. Available from: https://www.lifeblood.com.au/blood/learn-about-blood/iron-health
  7. 7.↵
    American Red Cross. What Donors Should Know About Iron and Blood Donation 2024 [cited 2024 July 7th]. Available from: https://www.redcrossblood.org/donate-blood/blood-donation-process/before-during-after/iron-blood-donation.html
  8. 8.↵
    Committee JUKUBTaTTSPA. Polycythaemia and Raised Haemoglobin 2023 [cited 2024]. Available from: https://www.transfusionguidelines.org/dsg/wb/guidelines/po006-polycythaemia
  9. 9.↵
    1. Olkhovskiy IA,
    2. Filina NG,
    3. Gorbenko AS,
    4. Stolyar MA,
    5. Kolotvina TB,
    6. Subbotina TN
    . Prevalence Of Mutations In Jak2 Among Blood Donors. Russian Journal Of Hematology And Transfusiology 2019; 63: 65-70.
    OpenUrl
  10. 10.↵
    1. Tagariello G,
    2. Di Gaetano R,
    3. Sartori R,
    4. Zanotto D,
    5. Belvini D,
    6. Radossi P, et al.
    The JAK2V617F tyrosine kinase mutation in blood donors with upper-limit haematocrit levels. Blood Transfus 2009; 7: 111-116.
    OpenUrlPubMed
  11. 11.↵
    1. Kamaruzzaman S
    , mohd noor nh, Hassan mn, Yusoff S, Abdullah WZ. Detection of JAK2 V617F Mutation among Donors with Erythrocytosis. J Clin Health Sci 2018; 3: 19.
    OpenUrl
  12. 12.↵
    1. Hopkins CK,
    2. Riley C,
    3. Pepkowitz S,
    4. Lopategui JR
    . Absence of the V617F JAK2 Mutation in 181 Healthy Donors. Blood 2007; 110: 4664.
    OpenUrl
  13. 13.↵
    1. Zanella A,
    2. Silvani C,
    3. Banfi P,
    4. Bellone A,
    5. Fumagalli G,
    6. Sirchia G
    . Screening and evaluation of blood donors with upper-limit hematocrit levels. Transfusion 1987; 27: 485-487.
    OpenUrl
  14. 14.
    1. Kandasamy D,
    2. Shastry S,
    3. O’Brien SF
    . Is high hemoglobin a hindrance factor for blood donation? A pilot observational study from the coastal region of India. Transfus Clin Biol 2021: 29: 147-152.
    OpenUrlPubMed
  15. 15.↵
    1. Tagariello G,
    2. Di Gaetano R,
    3. Sartori R,
    4. Zanotto D,
    5. Belvini D,
    6. Radossi P, et al.
    The JAK2v617f tyrosine kinase mutation in blood donors with upper-limit haematocrit level. Blood Transfus 2008.
  16. 16.↵
    Covidence Systematic Review Software, Veritas Health Innovation, Melbourne, Australia. Available from: Available at www.covidence.org
  17. 17.↵
    1. Sidon P,
    2. El Housni H,
    3. Dessars B,
    4. Heimann P
    . The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia 2006; 20: 1622.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.
    1. Bianchi P,
    2. Fermo E,
    3. Mozzi F,
    4. Marconi M,
    5. Zanella A
    . Presence of JAK2 V617F mutation in peripheral blood of blood donors with upper-limit hematocrit and platelet values. Blood 2007; 110: 2533.
    OpenUrl
  19. 19.↵
    1. Magnussen K,
    2. Hasselbalch HC,
    3. Ullum H,
    4. Bjerrum OW
    . Characterization of blood donors with high hemoglobin concentration. Vox Sanguinis 2013; 104: 110-114.
    OpenUrlPubMed
  20. 20.↵
    1. A. Al-Rubaie
    2. H, A. Khudeir M, Medical City BTH,
    3. M Al-Bayaa I
    , Dept. of Pathology CoMUoK. Detection of JAK2V617F tyrosine kinase mutation and estimation of serum erythropoietin in blood donors who have high hematocrit. J Fac Med Baghdad. 2014; 56: 395-400.
    OpenUrl
  21. 21.
    1. Kandasamy D,
    2. Shastry S,
    3. Chenna D,
    4. Mohan G
    . Blood donor deferral analysis in relation to the screening process: A single-center study from southern India with emphasis on high hemoglobin prevalence. J Blood Med 2020; 11: 327-334.
    OpenUrlPubMed
  22. 22.↵
    1. Gaddam M,
    2. Prakash P,
    3. Devegowda D,
    4. Kumar R
    . Analysis of JAK2V617F tyrosine kinase mutation in blood donors with erythrocytosis. A pilot study in a tertiary care teaching hospital of south India. J Blood Med 2022; 13: 439-446.
    OpenUrlPubMed
  23. 23.↵
    1. Kaizer H,
    2. Naik RP,
    3. Lobner K,
    4. Moliterno AR
    . JAK2 V617F Prevalence Study: Associations in the general population and vascular disease populations. Blood 2020; 136: 36.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Xu X,
    2. Zhang Q,
    3. Luo J,
    4. Xing S,
    5. Li Q,
    6. Krantz SB, et al.
    JAK2(V617F): Prevalence in a large Chinese hospital population. Blood 2007; 109: 339-342.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Camilla N,
    2. Stig EB,
    3. Børge GN,
    4. Klaus FK,
    5. Henrik SB
    . JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate. Haematologica 2014; 99: 1448-55.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Cordua S,
    2. Kjaer L,
    3. Skov V,
    4. Pallisgaard N,
    5. Hasselbalch HC,
    6. Ellervik C
    . Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population. Blood 2019; 134: 469-479.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Regimbeau M,
    2. Mary R,
    3. Hermetet F,
    4. Girodon F
    . Genetic Background of Polycythemia Vera. Genes 2022; 13: 637.
    OpenUrl
  28. 28.↵
    1. Steensma DP
    . JAK2 V617F in Myeloid Disorders: Molecular Diagnostic Techniques and Their Clinical Utility. J Mol Diagn 2006; 8:397-411.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. La Rocca F,
    2. Grieco V,
    3. Ruggieri V,
    4. Zifarone E,
    5. Villani O,
    6. Zoppoli P, et al.
    Superiority of Droplet Digital PCR Over Real-Time Quantitative PCR for JAK2 V617F allele mutational burden assessment in myeloproliferative neoplasms: A retrospective study. Diagnostics (Basel) 2020; 10: 143.
    OpenUrlPubMed
  30. 30.↵
    1. Vignon M,
    2. Jeziorowska D,
    3. Hirsch P,
    4. Legrand O,
    5. Casadevall N,
    6. Delhommeau F, et al.
    Clinical Implications for Patients with Low JAK2V617F Allele Burden. Blood 2012; 120: 1745.
    OpenUrl
  31. 31.↵
    1. Barbui T,
    2. Thiele J,
    3. Gisslinger H,
    4. Kvasnicka HM,
    5. Vannucchi AM,
    6. Guglielmelli P, et al.
    The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J 2018; 8 :15.
    OpenUrlPubMed
  32. 32.↵
    1. Piris-Villaespesa M,
    2. Álvarez-Larrán A,
    3. Saez-Marín A,
    4. Nuñez-Torrón C,
    5. Muñoz-Martin G,
    6. Sánchez R, et al.
    Development and validation of a sequential two-step algorithm for the screening of individuals with potential polycythaemia vera.v Sci Rep 2021; 11: 209.
    OpenUrl
  33. 33.↵
    1. Guglielmelli P,
    2. Loscocco GG,
    3. Mannarelli C,
    4. Rossi E,
    5. Mannelli F,
    6. Ramundo F, et al.
    JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis. Blood Cancer J 2021; 11: 199.
    OpenUrlPubMed
  34. 34.↵
    1. Stuckey R,
    2. Bilbao-Sieyro C,
    3. Segura-Díaz A,
    4. Gómez-Casares MT
    . Molecular studies for the early detection of philadelphia-negative myeloproliferative neoplasms. Int J Mol Sci 2023; 24.
  35. 35.↵
    1. Guo J,
    2. Walter K,
    3. Quiros PM,
    4. Gu M,
    5. Baxter EJ,
    6. Danesh J, et al.
    Inherited polygenic effects on common hematological traits influence clonal selection on JAK2V617F and the development of myeloproliferative neoplasms. Nature Genetics 2024; 56: 273-280.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Oren O,
    2. Small AM,
    3. Libby P
    . Clonal hematopoiesis and atherosclerosis. J Clin Invest 2024; 134.
  37. 37.↵
    1. Wouters HJCM,
    2. Mulder R,
    3. van Zeventer IA,
    4. Schuringa JJ,
    5. van der Klauw MM,
    6. van der Harst P, et al.
    Erythrocytosis in the general population: clinical characteristics and association with clonal hematopoiesis. Blood Advances 2020; 4: 6353-63.
    OpenUrlPubMed
  38. 38.↵
    1. Smith JR,
    2. Landaw SA. Smokers’ Polycythemia
    . New England Journal of Medicine 1978; 298: 6-10.
    OpenUrlCrossRefPubMedWeb of Science
  39. 39.↵
    1. Filion KB,
    2. Steffen LM,
    3. Duval S,
    4. Jacobs DR, Jr.,
    5. Blackburn H,
    6. Luepker RV
    . Trends in smoking among adults from 1980 to 2009: the Minnesota heart survey. Am J Public Health 2012; 102: 705-713.
    OpenUrlCrossRefPubMed
  40. 40.↵
    World Health Organization. Age-standardized estimates of current tobacco use, tobacco smoking and cigarette smoking. [Updated 2024; Accessed2 February 2024]. Available from: https://apps.who.int/gho/data/node.main.TOBAGESTDCURR?lang=en
  41. 41.↵
    1. Allahverdi N,
    2. Yassin M,
    3. Ibrahim M
    . Environmental factors, lifestyle risk factors, and host characteristics associated with philadelphia negative myeloproliferative neoplasm: A systematic review. Cancer Control 2021;28:10732748211046802.
    OpenUrlPubMed
  42. 42.↵
    1. Hazegh K,
    2. Bravo MD,
    3. Kamel H,
    4. Dumont L,
    5. Kanias T
    . The prevalence and demographic determinants of blood donors receiving testosterone replacement therapy at a large USA blood service organization. Transfusion 2020; 60: 947-954.
    OpenUrl
  43. 43.↵
    1. Van Buren NL,
    2. Hove AJ,
    3. French TA,
    4. Gorlin JB
    . Therapeutic Phlebotomy for Testosterone-Induced Polycythemia: A Blood Center’s Perspective. American Journal of Clinical Pathology 2020; 154: 33-37.
    OpenUrlPubMed
  44. 44.↵
    1. Berlin NI
    . Diagnosis and classification of the polycythemias. Semin Hematol 1975; 12: 339-351.
    OpenUrlPubMedWeb of Science
  45. 45.
    1. McMullin MF,
    2. Bareford D,
    3. Campbell P,
    4. Green AR,
    5. Harrison C,
    6. Hunt B, et al.
    Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol 2005; 130: 174-195.
    OpenUrlCrossRefPubMedWeb of Science
  46. 46.
    1. Vardiman JW,
    2. Harris NL,
    3. Brunning RD
    . The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-302.
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    1. Swerdlow SH CE,
    2. Harris NL,
    3. Jaffe ES,
    4. Pileri SA,
    5. Stein H,
    6. Thiele J
    . WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues: Lyon: International Agency for Research on Cancer.; 2017.
  48. 48.↵
    1. Barbui T,
    2. Thiele J,
    3. Gisslinger H,
    4. Kvasnicka HM,
    5. Vannucchi AM,
    6. Guglielmelli P, et al.
    The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J 2018; 8: 15.
    OpenUrlPubMed
  49. 49.↵
    1. Thiele J,
    2. Kvasnicka HM
    . The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Curr Hematol Malig Rep 2009; 4: 33-40.
    OpenUrlCrossRefPubMed
  50. 50.↵
    1. Mahe E,
    2. Pedersen KM,
    3. Çolak Y,
    4. Bojesen SE,
    5. Lynch T,
    6. Sinclair G, et al.
    JAK2-tree: a simple CBC-based decision rule to guide appropriate JAK2 V617F mutation testing. J Clin Pathol 2019; 72: 172-176.
    OpenUrlAbstract/FREE Full Text
  51. 51.↵
    1. Chin-Yee B,
    2. Bhai P,
    3. Cheong I,
    4. Matyashin M,
    5. Hsia CC,
    6. Kawata E, et al.
    A Rational Approach to JAK2 Mutation Testing in Patients with Elevated Hemoglobin: Results from the JAK2 Prediction Cohort (JAKPOT) Study. Journal of General Internal Medicine 2023; 38: 1828-1833.
    OpenUrlPubMed
  52. 52.↵
    1. Koseoglu FD,
    2. Keklik Karadag F,
    3. Bulbul H,
    4. Alici EU,
    5. Ozyilmaz B,
    6. Ozdemir TR
    . JAKCalc: A machine-learning approach to rationalized JAK2 testing in patients with elevated hemoglobin levels. Medicine (Baltimore) 2024; 103: e37751.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords